151 related articles for article (PubMed ID: 10764959)
41. Peripheral antinociceptive effects of the cyclic endomorphin-1 analog c[YpwFG] in a mouse visceral pain model.
Bedini A; Baiula M; Gentilucci L; Tolomelli A; De Marco R; Spampinato S
Peptides; 2010 Nov; 31(11):2135-40. PubMed ID: 20713109
[TBL] [Abstract][Full Text] [Related]
42. Analgesic effects of Tyr-W-MIF-1: a mixed mu2-opioid receptor agonist/mu1-opioid receptor antagonist.
Gergen KA; Zadina JE; Paul D
Eur J Pharmacol; 1996 Nov; 316(1):33-8. PubMed ID: 8982647
[TBL] [Abstract][Full Text] [Related]
43. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
44. DAMGO ([D-Ala2,NMePhe4,Gly-ol]enkephalin), but not DPLPE ([D-Pen2,L- Pen5]enkephalin), specifically inhibits methamphetamine-induced behavioral responses in the mouse.
Ukai M; Toyoshi T; Kameyama T
Neuropharmacology; 1993 Oct; 32(10):1019-24. PubMed ID: 8295712
[TBL] [Abstract][Full Text] [Related]
45. Differential regulation of adenylyl cyclase activity by mu and delta opioids in rat caudate putamen and nucleus accumbens.
Izenwasser S; Búzás B; Cox BM
J Pharmacol Exp Ther; 1993 Oct; 267(1):145-52. PubMed ID: 7901389
[TBL] [Abstract][Full Text] [Related]
46. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
Kamei J; Ohsawa M; Saitoh A; Iwamoto Y; Suzuki T; Misawa M; Nagase H; Kasuya Y
J Pharmacol Exp Ther; 1995 Aug; 274(2):700-6. PubMed ID: 7636731
[TBL] [Abstract][Full Text] [Related]
47. The role of mu- and delta- opioid receptors on the intestinal propulsion in rats.
Sbacchi M; La Regina A; Petrillo P; Tavani A
NIDA Res Monogr; 1986; 75():520-3. PubMed ID: 2828999
[TBL] [Abstract][Full Text] [Related]
48. DAMGO stimulates the hypothalamo-pituitary-adrenal axis through a mu-2 opioid receptor.
Eisenberg RM
J Pharmacol Exp Ther; 1993 Aug; 266(2):985-91. PubMed ID: 8394926
[TBL] [Abstract][Full Text] [Related]
49. Blockade of delta-opioid receptors prevents morphine-induced place preference in mice.
Suzuki T; Yoshiike M; Mizoguchi H; Kamei J; Misawa M; Nagase H
Jpn J Pharmacol; 1994 Sep; 66(1):131-7. PubMed ID: 7861658
[TBL] [Abstract][Full Text] [Related]
50. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
51. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine.
Heyman JS; Williams CL; Burks TF; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1988 Apr; 245(1):238-43. PubMed ID: 2834537
[TBL] [Abstract][Full Text] [Related]
52. Involvement of mouse μ-opioid receptor splice variants in the spinal antinociception induced by the dermorphin tetrapeptide analog amidino-TAPA.
Mizoguchi H; Watanabe C; Higashiya T; Takeda S; Moriyama K; Yonezawa A; Sato T; Komatsu T; Sakurada T; Sakurada S
Eur J Pharmacol; 2011 Jan; 651(1-3):66-72. PubMed ID: 21047509
[TBL] [Abstract][Full Text] [Related]
53. Different profile of electrocortical power spectrum changes after micro-infusion into the locus coeruleus of selective agonists at various opioid receptor subtypes in rats.
Bagetta G; De Sarro GB; Sakurada S; Rispoli V; Nisticò G
Br J Pharmacol; 1990 Nov; 101(3):655-61. PubMed ID: 1963804
[TBL] [Abstract][Full Text] [Related]
54. Differential antagonism of endomorphin-1 and endomorphin-2 supraspinal antinociception by naloxonazine and 3-methylnaltrexone.
Sakurada S; Hayashi T; Yuhki M; Fujimura T; Murayama K; Yonezawa A; Sakurada C; Takeshita M; Sato T; Zadina JE; Kastin AJ; Sakurada T
Peptides; 2002 May; 23(5):895-901. PubMed ID: 12084520
[TBL] [Abstract][Full Text] [Related]
55. Effects of selective opioid receptor antagonists on morphine-induced changes in striatal and limbic dopamine metabolism.
Piepponen TP; Ahtee L
Pharmacol Toxicol; 1995 Sep; 77(3):204-8. PubMed ID: 8884884
[TBL] [Abstract][Full Text] [Related]
56. Differential involvement of mu 1-opioid receptors in dermorphin tetrapeptide analogues-induced antinociception.
Mizoguchi H; Yuhki M; Watanabe H; Hayashi T; Sakurada C; Yonezawa A; Sakurada T; Sakurada S
Eur J Pharmacol; 2004 Feb; 486(1):19-24. PubMed ID: 14751403
[TBL] [Abstract][Full Text] [Related]
57. G protein activation by endomorphins in the mouse periaqueductal gray matter.
Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
[TBL] [Abstract][Full Text] [Related]
58. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
59. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
Mjanger E; Yaksh TL
J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
[TBL] [Abstract][Full Text] [Related]
60. Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit.
Feng P; Rahim RT; Cowan A; Liu-Chen LY; Peng X; Gaughan J; Meissler JJ; Adler MW; Eisenstein TK
Eur J Pharmacol; 2006 Mar; 534(1-3):250-7. PubMed ID: 16513108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
